Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$411M |
| 2 |
Microsoft
MSFT
|
+$309M |
| 3 |
ExxonMobil
XOM
|
+$258M |
| 4 |
Johnson & Johnson
JNJ
|
+$221M |
| 5 |
GE Aerospace
GE
|
+$217M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BRCM
BROADCOM CORP CL-A
BRCM
|
+$58.7M |
| 2 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$57.9M |
| 3 |
CB
CHUBB CORPORATION
CB
|
+$54.7M |
| 4 |
Stellantis
STLA
|
+$25.2M |
| 5 |
GMCR
KEURIG GREEN MTN INC
GMCR
|
+$20M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.83% |
| 2 | Healthcare | 14.67% |
| 3 | Consumer Discretionary | 10.51% |
| 4 | Consumer Staples | 10.31% |
| 5 | Industrials | 10.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AC
2576
DELISTED
Associated Capital Group
AC
| $166K | ﹤0.01% |
6,231
+1,407
| +29% | +$38.7K |
|
2577
Ameresco
AMRC
$1.38B
| $163K | ﹤0.01% |
35,300
+11,100
| +46% | +$56.5K |
|
2578
Ocular Therapeutix
OCUL
$2.11B
| $156K | ﹤0.01% |
16,800
+3,800
| +29% | +$28.8K |
|
|
ENTL
2579
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $155K | ﹤0.01% |
8,900
+2,000
| +29% | +$32.4K |
|
2580
Addus HomeCare
ADUS
$2.22B
| $152K | ﹤0.01% |
9,250
+2,250
| +32% | +$46.5K |
|
2581
Larimar Therapeutics
LRMR
$452M
| $148K | ﹤0.01% |
1,917
+400
| +26% | +$31.6K |
|
2582
Green Brick Partners
GRBK
$3.08B
| $145K | ﹤0.01% |
19,900
+4,500
| +29% | +$27.8K |
|
2583
Boot Barn
BOOT
$5.08B
| $142K | ﹤0.01% |
15,800
+3,600
| +30% | +$32.1K |
|
2584
W&T Offshore
WTI
$584M
| $141K | ﹤0.01% |
66,350
+12,550
| +23% | +$25.5K |
|
|
UDF
2585
DELISTED
UNITED DEV FDG IV COM SHS OF BENE INT (TX)
UDF
| $141K | ﹤0.01% |
45,282
+13,082
| +41% | +$116K |
|
|
OMED
2586
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $138K | ﹤0.01% |
14,200
+3,200
| +29% | +$37.6K |
|
|
MR
2587
DELISTED
Montage Resources Corporation Common Stock
MR
| $137K | ﹤0.01% |
6,533
+1,133
| +21% | +$18.5K |
|
|
IMDZ
2588
DELISTED
Immune Design Corp.
IMDZ
| $136K | ﹤0.01% |
10,900
+2,500
| +30% | +$28.9K |
|
|
PAMT
2589
PAMT Corp
PAMT
$288M
| $133K | ﹤0.01% |
18,000
+4,000
| +29% | +$27.5K |
|
|
UPL
2590
DELISTED
Ultra Petroleum Corp. Common Stock
UPL
| $130K | ﹤0.01% |
270,247
+50,150
| +23% | +$59.2K |
|
|
CHMA
2591
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $128K | ﹤0.01% |
14,600
+3,300
| +29% | +$35.7K |
|
|
PZN
2592
DELISTED
Pzena Investment Management, Inc. Class A
PZN
| $122K | ﹤0.01% |
16,900
+4,000
| +31% | +$28.1K |
|
|
GEN
2593
DELISTED
Genesis Healthcare, Inc.
GEN
| $122K | ﹤0.01% |
54,900
+12,400
| +29% | +$28K |
|
|
NWBO
2594
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
| $121K | ﹤0.01% |
85,600
+18,400
| +27% | +$36.3K |
|
|
OREX
2595
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $120K | ﹤0.01% |
22,180
+7,620
| +52% | +$99K |
|
2596
Alico
ALCO
$309M
| $119K | ﹤0.01% |
4,500
+1,000
| +29% | +$28K |
|
2597
Live Oak Bancshares
LOB
$1.98B
| $116K | ﹤0.01% |
8,100
-6,800
| -46% | -$91.9K |
|
|
CIVI
2598
DELISTED
Civitas Resources
CIVI
| $112K | ﹤0.01% |
654
+123
| +23% | +$32.6K |
|
|
CJES
2599
DELISTED
C&J ENERGY SVCS LTD
CJES
| $105K | ﹤0.01% |
77,050
+15,750
| +26% | +$33.4K |
|
|
VSLR
2600
DELISTED
VIVINT SOLAR, INC.
VSLR
| $104K | ﹤0.01% |
40,650
+18,450
| +83% | +$119K |
|
Similar funds
Swiss National Bank's Q1 2016 Portfolio in Review
As of Q1 2016, Swiss National Bank held 2,649 positions worth $54.5B, up 32% from $41.3B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Swiss National Bank deployed $13.6B of net new capital in Q1 2016, opening 6 new positions and adding to 2,585 existing holdings. Its largest new stake was Ferrari: 823,472 shares worth $32.9M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was Stellantis, an estimated $25.2M trimmed.
- Swiss National Bank's largest Q1 2016 buy was Ferrari: 823,472 shares worth $32.9M.
- Swiss National Bank added most to Apple in Q1 2016, an estimated $411M increase.
- Swiss National Bank's biggest Q1 2016 reduction was Stellantis, cutting an estimated $25.2M.
- Swiss National Bank fully exited BROADCOM CORP CL-A in Q1 2016, selling an estimated $58.7M.
- Swiss National Bank's ten largest holdings make up 15% of its $54.5B portfolio in Q1 2016.
- Swiss National Bank opened 6 new positions and closed 38 in Q1 2016.
- Swiss National Bank's portfolio value rose 32% quarter-over-quarter to $54.5B.
Based on Swiss National Bank's 13F filing for Q1 2016, filed 4 May 2016.